Cannabis: Legalizing the Leaf - [Business Breakdowns, EP. 42]

Episode Summary

Executive Summary: The episode frames U.S. cannabis as a fast-growing but structurally inefficient industry shaped by state-by-state legalization, federal prohibition, and limited access to capital. Jeff Hoffman argues the legal market is still early, public MSOs can compound rapidly, and catalysts like safe banking and New York/New Jersey legalization could unlock major upside.

Main Topics: Cannabis market size and growth (Priority: 5/5): Cannabis is described as a ~$100B industry today, with most consumption still illegal. Growth is driven by state legalization and migration from illicit to legal channels, not new product creation. Federal prohibition vs. state legalization (Priority: 5/5): The conversation explains the legal patchwork: cannabis remains federally Schedule I, while many states allow medical or adult-use sales, creating a fragmented operating environment. Value chain and MSO business model (Priority: 5/5): The podcast walks through the seed-to-sale ecosystem, emphasizing vertically integrated multi-state operators (MSOs) that cultivate, process, distribute, and retail within each state’s rules. Capital markets inefficiency (Priority: 5/5): U.S. cannabis equities are hindered by exchange exclusions, custody issues, and minimal institutional ownership, which depress valuations despite strong growth and margins. Economics, margins, and limited-license states (Priority: 4/5): Scaled MSOs can achieve attractive gross and EBITDA margins, especially in limited-license states where supply is constrained and pricing remains strong. Catalysts and reform outlook (Priority: 4/5): Safe banking, uplisting, and incremental state-level legalization are presented as the most likely near-term catalysts, while full federal legalization is viewed as less likely soon. Consumer evolution and product innovation (Priority: 4/5): The market is expected to broaden beyond flower and smoking into edibles, beverages, and new cannabinoid-based products as older and more mainstream consumers adopt the category.

Key Arguments: The legal market is still underpenetrated: most cannabis consumption remains illicit, so legalization mainly shifts demand rather than requiring total market creation. Each U.S. state behaves like its own country because product cannot cross state lines, forcing companies to recreate infrastructure in every market they enter. Federal illegality makes the business structurally inefficient by blocking major exchanges, restricting bank access, and limiting institutional ownership. Limited-license states create outsized economics because fixed license counts constrain supply and allow MSOs to earn strong margins. Scaled MSOs can be highly profitable, with strong gross margins and EBITDA margins, but taxes and financing costs remain punitive because cannabis expenses are often not tax-deductible. Safe banking is the most realistic near-term reform; it would reduce cash risk, improve banking access, and likely expand liquidity for public equities. The long-term opportunity is tied to product innovation, national brands, and new form factors that legal operators can develop faster than the illicit market. Competition is less about other MSOs and more about replacing the illicit market with a better, safer, legal consumer experience.

Data Points: Total cannabis market size: $100 billion - Approximate total U.S. cannabis market today, including legal and illegal sales. Legal market size: $25 billion - Estimated current legal cannabis market in the U.S. Illegal market size: $75 billion - Estimated current illicit cannabis market in the U.S. Legal market size in 2019: $11 billion - Referenced as the U.S. legal cannabis market size in 2019. Legal market size in 2018: $7-8 billion - Approximate U.S. legal cannabis market size in 2018. Projected legal market size in 2025: $45 billion - Expected U.S. legal cannabis market size in 2025. Support for adult-use legalization: 68% - Share of U.S. adults supporting legalized cannabis, up from about 40% a decade earlier. Democratic support: 80% - Democrats supporting adult-use legalization. Independent support: 70% - Independents supporting adult-use legalization. Republican support: 50% - Republicans supporting adult-use legalization. States with medical cannabis: 37 states - Number of states with medical cannabis legalization at the time of discussion. States with adult-use cannabis: 18 states - Number of states with recreational/adult-use legalization at the time of discussion. MSO revenue growth: ~50% in 2022 - Expected growth for U.S. multi-state operators, according to the guest. Overall market growth: ~20% in 2022 - Expected growth for the broader cannabis market. Institutional ownership of MSOs: ~4% - Estimated share of MSO ownership held by institutional holders. Top five MSO market cap: $20 billion - Combined market capitalization of the top five U.S. multi-state operators. Canadian LP market cap example: $4.5 billion - Example given for Canopy Growth, used to compare with U.S. operators. MSO valuation: ~8x 2022 EBITDA - Average trading multiple cited for scaled U.S. MSOs. Forward MSO valuation: ~4-5x EBITDA - Valuation implied on 2024 EBITDA estimates. Potential long-term legal market: $75-100 billion - Guest’s view of the potential U.S. legal market over the next decade. Potential long-term market cap: $450-600 billion - Estimated value if the legal market reaches $75-100B with 30% EBITDA margins and a 20x multiple. Safe banking support: Passed House five times - House passage history cited for the SAFE Banking Act. Safe banking co-sponsors: 180 co-sponsors - Bipartisan support level cited for the SAFE Banking Act. MSO gross margins: at least 50% - Scaled MSO gross margin estimate. MSO EBITDA margins: at least 30% - Scaled MSO EBITDA margin estimate. Effective tax rate: 50-70% - Guest’s estimate of effective tax burden due to non-deductibility under federal illegality. Cost of debt for scaled MSOs: ~8% (about 10% all-in) - Borrowing cost estimate for more established operators. All-in indoor grow cost: about $700 per unit - Approximate cost to grow indoors, as described in wholesale economics. Wholesale vs retail example: $2,500 per pound to $5,000 per pound - Illustrative pricing spread from grower to retailer in New Jersey example. Retail gross margins: ~45-50% - Sub-scale retail margin estimate. Four-wall contribution margin: ~20-25% - Typical sub-scale dispensary contribution margin. Scaled retail four-wall margin: ~35% - Margin estimate for efficient scaled MSO dispensaries. Florida store cap: No cap - Florida highlighted as a limited-license state with no cap on dispensaries or canopy. Connecticut store cap: 4 stores - Example of a limited-license state constraint. Minnesota store cap: 2 stores - Example of a very limited license regime. New York store cap: 10 stores - Example of a limited license regime. Illinois store cap: 10 stores - Example of a limited license regime. Illinois sales growth: $250 million to ~$2 billion run-rate - Growth from medical sales in 2019 to run-rate adult-use legal sales by late 2021/early 2022. Out-of-state share in Illinois: 30% - Share of Illinois cannabis sales reportedly coming from non-residents. Colorado revenue per capita: over $400 - Per-capita cannabis revenue in Colorado in a mature market example. California tax rate: 40% - Total tax burden cited for cannabis purchases in California. Massachusetts tax rate: 20% - Total tax burden cited for cannabis purchases in Massachusetts. Monthly cannabis users: ~10% of consumers - Estimated share of consumers using cannabis monthly versus alcohol. Monthly alcohol users: 55-60% of consumers - Estimated share of consumers using alcohol monthly. Annual cannabis spend per consumer: $2,700 - Average annual spend cited for cannabis consumers. Annual alcohol spend per consumer: $1,400 - Average annual spend cited for alcohol consumers. Dual users preferring cannabis: 44% - Share of consumers who use both cannabis and alcohol and prefer cannabis. Dual users preferring alcohol: 30% - Share of consumers who use both and prefer alcohol. Cannabis-related consumer relief in Florida study: 80% - Patients reporting good amount or complete relief across symptom categories. Prescription reduction/discontinuation in Florida study: 65% - Patients reporting reduction or discontinuation of at least one prescription or OTC drug after cannabis use. Alcohol-linked deaths: 95,000 annually - Statistic cited to compare public-health risk with cannabis. Opioid-linked deaths: 50,000 annually - Statistic cited to compare public-health risk with cannabis. Cannabis lethal dose claim: 1,500 pounds in 15 minutes - A cited study suggesting an implausibly high amount needed to die from cannabis consumption.

Pivotal Quotes: "Every state can be thought of as its own country. You're not allowed to bring product across state lines." — Jeff Hoffman: Explaining why cannabis companies must duplicate infrastructure in each state and cannot operate like normal interstate businesses. "This is a cash business. You cannot go use a credit card at a dispensary." — Jeff Hoffman: Describing the banking, security, and operational inefficiencies created by federal illegality. "Competition is not another MSO. Competition is the illicit market." — Jeff Hoffman: Framing the real battle for legal operators as conversion of consumers from illegal to legal channels.

Implications: The industry offers outsized upside if reform expands access to banking, liquidity, and interstate-like capital formation. Investors should focus on operators with scale, execution, and state-specific advantages rather than headline valuations alone.